EUCTR2009-010423-58-ES进行中（未招募）1 期
Evaluación de la efectividad y la tolerabilidad de clorhidrato de tapentadol de liberación prolongada y de clorhidrato de tapentadol de liberación inmediata a demanda en pacientes con dolor crónico severo no controlado debido a artrosis de rodilla no tratados con regularidad o en tratamiento con analgésicos de los escalones I o II de la clasificación de la OMS.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Key inclusion criteria (general)
- •Subjects have signed an Informed Consent Form indicating that they understand the purpose of and the procedures required for the trial and are willing to participate in it.
- •Subjects are men or non-pregnant, non-lactating women. Sexually active women must be postmenopausal, surgically sterile, or practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch, male partner sterilization) before entry and throughout the trial. Women of childbearing potential must have a negative pregnancy test at screening.
- •Subjects must be appropriately communicative to verbalize and to differentiate with regard to location and intensity of the pain.
- •Key inclusion criteria (trial specific) - at the Screening Visit
- •Subjects must be at least 40 years of age.
- •Subjects must have a diagnosis of osteoarthritis of the knee based on the American College of Rheumatology (ACR) classification criteria:
- •Knee pain and Radiographic osteophytes or Knee pain and Aged 40 years or above, and Morning stiffness of 30 minutes of duration or more, and Crepitus on motion.
- •Subjects must have pain at the reference joint which has been present for at least 3 months.
- •Subject?s pain must require a strong analgesic (defined as WHO Step III) as judged by the Investigator.
- •Subjects must report a rate of satisfaction with their previous analgesic regimen not exceeding ?fair? on a subject satisfaction with treatment scale (5-point VRS).
- •If under regular, daily pretreatment:
- •? Subjects must be taking a WHO Step I or Step II analgesic medication for osteoarthritis of the knee on a daily basis for at least 2 weeks prior to the Screening Visit.
- •? The Investigator considers dose increase of WHO Step I analgesics (as mono- or combination therapy) and/or continuation with or dose increase of WHO Step II analgesics inadequate for the individual subject, whatever applicable.
- •? Subjects must have an average pain intensity score (NRS 3) greater than 5 points during the last 3 days prior to the Screening Visit.
- •If no regular analgesic pretreatment is reported:
- •Subjects must have an average pain intensity score (NRS-3) greater than 6 points in the last 3 days prior to the Screening Visit and related to osteoarthritis.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Key exclusion criteria (general)
- •Presence of a clinically significant disease or laboratory findings that in the Investigator?s opinion may affect efficacy or safety assessments.
- •Presence of active systemic or local infection, that may, in the opinion of the Investigator, affect the efficacy, quality of life/function or safety assessments.
- •History of alcohol or drug abuse, or suspicion thereof in the Investigator?s judgment.
- •Presence of concomitant autoimmune inflammatory conditions.
- •Known history of or laboratory values reflecting severe renal impairment.
- •Known history of moderately or severely impaired hepatic function.
- •History of or active hepatitis B or C within the past 3 months or history of HIV infection.
- •History of seizure disorder or epilepsy.
- •Any of the following within 1 year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm. Severe traumatic brain injury within 15 years (consisting of 1 or more of the following: brain contusion, intracranial hematoma, either unconsciousness or post-traumatic amnesia lasting more than 24 h) or residual sequelae suggesting transient changes in consciousness.
- •Pregnant or breast-feeding.
- •History of allergy to, or hypersensitivity to tapentadol hydrochloride or its excipients, or contraindications related to tapentadol hydrochloride including:
- •Subjects with acute or severe bronchial asthma or hypercapnia.
- •Subjects who have or are suspected of having paralytic ileus.
- •Employees of the Investigator or trial site, with direct involvement in this trial or other trials under the direction of the Investigator or trial site, as well as family members of employees of the Investigator.
- •Participation in another trial concurrently or within 4 weeks prior to the Screening Visit.
- •Known to or suspected of not being able to comply with the protocol and the use of the IMPs.
- •Use of monoamine oxidase inhibitors within 14 days before the Screening Visit.
- •Non-stable dosing of selective serotonin reuptake inhibitors within 30 days before the Screening Visit (Doses must remain stable during the trial).
- •Key exclusion criteria (trial specific)
- •Osteoarthritis in a flare state.
- •Use of intra-articular injections of hyaluronic acid in the reference joint within 3 months before the Screening Visit.
- •Presence of conditions other than osteoarthritis of the reference joint that could confound the assessment or self-evaluation of pain, e.g., anatomical deformities, significant skin conditions such as abscess or syndromes with widespread pain such as fibromyalgia. Subjects with osteoarthritis at joints other than the reference joint will not be excluded as long as the reference joint is the source of main pain and disability.
- •History and clinical signs at the reference joint of crystal-induced (e.g., gout, pseudo-gout), metabolic, infectious and autoimmune disease.
- •Any concomitant painful condition that could interfere with the subjects? trial assessments or with their ability to differentiate the current joint pain from other painful conditions.
- •Any painful procedures during the t
研究者
相似试验
进行中（未招募）
1 期
Evaluación de la efectividad y la tolerabilidad de clorhidrato de tapentadol de liberación prolongada y de clorhidrato de tapentadol de liberación inmediata a demanda en pacientes con dolor crónico severo debido a artrosis de rodilla en tratamiento con analgésicos del Escalón III de la clasificación de la OMS y que presentan problemas de tolerabilidad.Dolor debido a osteartritis de rodillaMedDRA version: 9.1 Level: LLT Classification code 10031161 Term: OsteoarthritisEUCTR2009-010425-39-ESGrünenthal GmbH180
进行中（未招募）
不适用
Evaluación de la efectividad y la tolerabilidad de clorhidrato de tapentadol de liberación prolongada y de clorhidrato de tapentadol de liberación inmediata a demanda en pacientes con lumbalgia crónica severa de origen nociceptivo, neuropático o mixto en tratamiento con analgésicos del escalón III de la clasificación de la OMS y que presentan problemas de tolerabilidadEUCTR2009-010428-25-ESGrünenthal GmbH180
进行中（未招募）
1 期
Evaluación de la efectividad y la tolerabilidad de clorhidrato de tapentadol de liberación prolongada y de clorhidrato de tapentadol de liberación inmediata a demanda en pacientes con lumbalgia crónica severa no controlada de origen nociceptivo, neuropático o mixto no tratados con regularidad o en tratamiento con analgésicos de los Escalones I o II de la clasificación de la OMSEUCTR2009-010427-12-ESGrünenthal GmbH
进行中（未招募）
不适用
Evaluation de l'efficacité et de la tolérance d'un anticorps monoclonal anti-CD20 : Rituximab (Mabthera(R)) dans le traitement des rechutes de pemphigoïde bulleuse - Rituximab 2Pemphigoïde bulleuseEUCTR2006-005744-92-FRCHU - Hôpitaux de Rouen
进行中（未招募）
不适用
Evaluation de l'efficacité et de la tolérance d'un traitement court de 7 jours par ceftriaxone intraveineux le 1er jour puis par cefixime per os du 2éme au 7éme jours dans la prise en charge aux urgences de la pyélonéphrite aigue simple chez la femme de 18 à 65 ans.pyélonéphrite aigüeEUCTR2010-023697-39-FRCHU de Clermont-Ferrand